Paul M. Barr, MD

Paul M. Barr, MD, discusses the clinical implications of the long-term results of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Paul M. Barr, MD, discusses the rationale for the long-term analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Paul M. Barr, MD, discusses the next steps of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Paul M. Barr, MD, discusses the next steps with the combination of umbralisib, ublituximab, and venetoclax in chronic lymphocytic leukemia.

Paul M. Barr, MD, discusses the safety profile of umbralisib plus ublituximab and venetoclax in chronic lymphocytic leukemia.

Paul M. Barr, MD, discusses the need to develop novel therapies in chronic lymphocytic leukemia.

Paul M. Barr, MD, Wilmot Cancer Institute, University of Rochester, discusses novel combination strategies in chronic lymphocytic leukemia (CLL).

Paul M. Barr, MD, Wilmot Cancer Institute, University of Rochester, discusses the results of a phase I/II study evaluating the combination of umbralisib, ublituximab, and venetoclax (Venclexta) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).